Left atrial appendage closure in very elderly patients in the French National Registry.
Atrial Fibrillation
Epidemiology
Stroke
Journal
Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087
Informations de publication
Date de publication:
18 Oct 2023
18 Oct 2023
Historique:
received:
23
04
2023
accepted:
19
08
2023
pubmed:
10
10
2023
medline:
10
10
2023
entrez:
9
10
2023
Statut:
aheadofprint
Résumé
Left atrial appendage closure (LAAC) is recommended to decrease the stroke risk in patients with atrial fibrillation and contraindications to anticoagulation. However, age-stratified data are scarce. The aim of this study was to provide information on the safety and efficacy of LAAC, with emphasis on the oldest patients. A nationwide, prospective, multicentre, observational registry was established by 53 French cardiology centres in 2018-2021. The composite primary endpoint included ischaemic stroke, systemic embolism, and unexplained or cardiovascular death. Separate analyses were done in the groups <80 years and ≥80 years. Among the 1053 patients included, median age was 79.7 (73.6-84.3) years; 512 patients (48.6%) were aged ≥80 years. Procedure-related serious adverse events were non-significantly more common in octogenarians (7.0% vs 4.4% in patients aged <80 years, respectively; p=0.07). Despite a higher mean CHA Despite a higher mean CHA ClinicalTrials.gov Registry (NCT03434015).
Identifiants
pubmed: 37813560
pii: heartjnl-2023-322871
doi: 10.1136/heartjnl-2023-322871
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT03434015']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Wissam Abi-Khalil
(W)
Nicolas Amabile
(N)
Sebastien Armero
(S)
David Attias
(D)
Nathalie Behar
(N)
Loic Belle
(L)
Bernard Bertrand
(B)
Hamza Bhugallo
(H)
Jacques Bille
(J)
Guillaume Bonnet
(G)
Serge Boveda
(S)
Camille Brasselet
(C)
François Brigadeau
(F)
Adrien Carabelli
(A)
Frederic Casassus
(F)
Didier Champagnac
(D)
Laure Champ-Rigot
(L)
Marion Chatot
(M)
Romain Chopard
(R)
Vlad Ciobotaru
(V)
Jean-Michel Clerc
(JM)
Olivier Com
(O)
Nicolas Combes
(N)
Bertand Comet
(B)
Philippe Commeau
(P)
Antoine Da Costa
(AD)
Olivier Darremont
(O)
Pascal Defaye
(P)
Bruno Degand
(B)
Jean-Claude Deharo
(JC)
Franck Digne
(F)
Gregory Ducrocq
(G)
Cyril Durand
(C)
Meyer Elbaz
(M)
Romain Eschalier
(R)
Bruno Farah
(B)
Philippe Garot
(P)
Richard Gelisse
(R)
Mathieu Granier
(M)
Paul Guedeney
(P)
Benoit Guy-Moyat
(B)
Sebastien Hascoet
(S)
Jean-Sylvain Hermida
(JS)
Jerome Horvilleur
(J)
Hassan Hosseini
(H)
David Huchette
(D)
Xavier Iriart
(X)
Peggy Jacon
(P)
Laurence Jesel-Morel
(L)
Patrick Joly
(P)
Regis Ketelers
(R)
Khalife Khalife
(K)
Didier Klug
(D)
Philippe Le Corvoisier
(PL)
Antoine Lepillier
(A)
François Lesaffre
(F)
Sebastien Levesque
(S)
Luc Lorgis
(L)
Jacques Mansourati
(J)
Eloi Marijon
(E)
Francois Massin
(F)
Nicolas Meneveau
(N)
Gilles Montalescot
(G)
Ghassan Moubarak
(G)
Jean-Luc Pasquie
(JL)
Bertrand Pierre
(B)
Olivier Piot
(O)
Maxime Pons
(M)
Batric Popovic
(B)
Gilles Rioufol
(G)
Cecile Romeyer
(C)
Arnaud Savoure
(A)
Iradj Sobhani
(I)
Emmanuel Teiger
(E)
Jean-Benoit Thambo
(JB)
Jean-Yves Wiedemann
(JY)
Salem Younsi
(S)
Informations de copyright
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: ET and PLC received unrestricted research grants from Boston Scientific and St Jude Medical for this study. PG is the medical director and shareholder of CERC (Cardiovascular European Research Center) and received speaker’s and advisory fees from Abbott and Boston Scientific. GR is proctor for Boston Scientific. RE is consultant and has performed proctoring for Boston Scientific and Abbott. None for all other authors.